Research Article
Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer
Table 1
Clinical And histological characteristics of samples used to validate the metastatic potential score model.
| | Case | Control |
| | 13 | 39 | Age | | Mean | 59.5 | 59.1 | Median | 61 | 58 | Standard deviation | 7.1 | 7.3 | Range | 46–67 | 46–73 | Race | | Asian | 0 (0%) | 1 (1.9%) | Black | 1 (1.9%) | 4 (7.7%) | Unknown | 0 (0%) | 2 (3.8%) | White Non-Hispanic | 12 (23.1%) | 32 (61.5%) | Clinical stage | | T1C | 4 (7.7%) | 23 (44.2%) | T2 | 5 (9.6%) | 16 (30.8%) | T3 | 4 (7.7%) | 0 (0%) | T4 | 0 (0%) | 0 (0%) | Biopsy Gleason score | | 5 | 0 (0%) | 0 (0%) | 6 | 4 (7.7%) | 26 (50%) | 7 | 7 (13.5%) | 10 (19.2%) | 8 | 2 (3.8%) | 2 (3.8%) | 9 | 0 (0%) | 1 (1.9%) | Prediagnosis biopsy PSA (ng/mL) | | Median | 6.9 | 5.6 | <4 | 2 (3.8%) | 6 (11.5%) | 4–10 | 6 (11.5%) | 24 (46.2%) | >10 | 4 (7.7%) | 7 (13.5%) | Pretreatment PSA (ng/mL) | | Median | 12.8 | 5.6 | <4 | 2 (3.8%) | 7 (13.5%) | 4–10 | 4 (7.7%) | 26 (50%) | >10 | 7 (13.5%) | 6 (11.5%) |
|
|